Cargando…

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients

INTRODUCTION: Recent advances in molecular diagnostics allow diffuse gliomas to be classified based on their genetic changes into distinct prognostic subtypes. However, a systematic analysis of all molecular markers has thus far not been performed; most classification schemes use a predefined and se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Draaisma, Kaspar, Wijnenga, Maarten M. J., Weenink, Bas, Gao, Ya, Smid, Marcel, Robe, P., van den Bent, Martin J., French, Pim J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690424/ https://www.ncbi.nlm.nih.gov/pubmed/26699864 http://dx.doi.org/10.1186/s40478-015-0265-4

Ejemplares similares

Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens
por: Weenink, Bas, et al.
Publicado: (2019)

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma
por: Wijnenga, Maarten M. J., et al.
Publicado: (2018)

Tumor mutational burden is associated with poor outcomes in diffuse glioma
por: Wang, Lihong, et al.
Publicado: (2020)

The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma
por: van der Voort, Sebastian R., et al.
Publicado: (2021)

Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma
por: Bai, Ming, et al.
Publicado: (2022)

Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation
por: Wijnenga, Maarten M J, et al.
Publicado: (2023)

Does early resection of presumed low-grade glioma improve survival? A clinical perspective
por: Wijnenga, Maarten M. J., et al.
Publicado: (2017)

Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups
por: Wijnenga, Maarten M J, et al.
Publicado: (2019)

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
por: Weenink, Bas, et al.
Publicado: (2020)

Glioblastomas within the Subventricular Zone Are Region-Specific Enriched for Mesenchymal Transition Markers: An Intratumoral Gene Expression Analysis
por: Dalemans, Diana J. Z., et al.
Publicado: (2021)

GFAP Alternative Splicing and the Relevance for Disease – A Focus on Diffuse Gliomas
por: van Asperen, Jessy V., et al.
Publicado: (2022)

Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning
por: van der Voort, Sebastian R, et al.
Publicado: (2022)

Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas
por: van de Geer, Wesley S, et al.
Publicado: (2021)

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
por: Nikbakht, Hamid, et al.
Publicado: (2016)

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
por: Lee, Yujin, et al.
Publicado: (2017)

Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment
por: Trautwein, Christoph, et al.
Publicado: (2022)

Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
por: Taylor, Kathryn R, et al.
Publicado: (2014)

Lack of B and T cell reactivity towards IDH1(R132H) in blood and tumor tissue from LGG patients
por: Weenink, Bas, et al.
Publicado: (2019)

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
por: Yu, Guangyang, et al.
Publicado: (2021)

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2020)

Genetic Alterations in Glioma
por: Bralten, Linda B. C., et al.
Publicado: (2011)

Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI
por: Gu, Taifu, et al.
Publicado: (2021)

PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis
por: Han, Feng, et al.
Publicado: (2016)

Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2022)

Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis
por: De Leeuw, Beverly I, et al.
Publicado: (2019)

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
por: Mirchia, Kanish, et al.
Publicado: (2020)

Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features
por: Shboul, Zeina A., et al.
Publicado: (2020)

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
por: Berns, E. M., et al.
Publicado: (1998)

Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas
por: Kazarian, Eve, et al.
Publicado: (2021)

Cognitive impairments are independently associated with shorter survival in diffuse glioma patients
por: van Kessel, Emma, et al.
Publicado: (2020)

Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas
por: Bredel, Markus, et al.
Publicado: (2023)

Diffusion Tensor Histogram Analysis of Pediatric Diffuse Intrinsic Pontine Glioma
por: Steffen-Smith, Emilie A., et al.
Publicado: (2014)

PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
por: Khadka, Prasidda, et al.
Publicado: (2022)

TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas
por: Gao, Ke, et al.
Publicado: (2015)

Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma
por: van Kessel, Emma, et al.
Publicado: (2022)

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas
por: Zhang, Zhen-Yu, et al.
Publicado: (2015)

Chromatin mutations in pediatric high grade gliomas
por: Voon, Hsiao P. J., et al.
Publicado: (2023)

Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment
por: van Kessel, Emma, et al.
Publicado: (2017)

IDH-1(R132H) mutation status in diffuse glioma patients: implications for classification
por: Wang, Peng-fei, et al.
Publicado: (2016)

Fatal Postpartum Hemorrhage in Diffuse Midline Glioma with H3-K27M Mutation
por: Miyazaki, Takeshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s5dh5p8sqdkh0n5mu2ohomp0dl